18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy

Rosenbaum-Krumme, Sandra; Görges, Rainer; Bockisch, Andreas; Binse, Ina

doi:10.1007/s00259-012-2065-4

Cited by 72 publications

(69 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Razfar et al evaluated the likelihood that a PET scan would change management in this scenario, and found that a PET scan changed the treatment plan in 28.2% of cases, which is similar to the present findings (21). There is a smaller body of literature describing the use of the PET scan for initial staging in intermediate-to high-risk patients with conflicting conclusions regarding its utility (10,22). Others have described the use of the PET scan in the evaluation of patients with persistently elevated thyroglobulin antibodies, and found about half of patients have disease identified on a PET scan (14,15).…”

Section: Discussionsupporting

confidence: 77%

See 1 more Smart Citation

Evaluating Positron Emission Tomography Use in Differentiated Thyroid Cancer

Wiebel

Esfandiari

Papaleontiou

et al. 2015

Thyroid

View full text Add to dashboard Cite

Background: Using the Surveillance, Epidemiology, and End Results-Medicare database, a substantial increase was found in the use of positron emission tomography (PET) scans after 2004 in differentiated thyroid cancer (DTC) patients. The reason for the increased utilization of the PET scan was not clear based on available the data. Therefore, the indications for and outcomes of PET scans performed at an academic institution were evaluated. Methods: A retrospective cohort study was performed of DTC patients who underwent surgery at the University of Michigan Health System from 2006 to 2011. After identifying patients who underwent a PET scan, indications, rate of positive PET scans, and impact on management were evaluated. For positive scans, the location of disease was characterized, and presence of disease on other imaging was determined. Results: Of the 585 patients in the cohort, 111 (19%) patients had 200 PET scans performed for evaluation of DTC. Indications for PET scan included: elevated thyroglobulin and negative radioiodine scan in 52 scans (26.0%), thyroglobulin antibodies in 13 scans (6.5%), rising thyroglobulin in 18 scans (9.0%), evaluation of abnormality on other imaging in 22 scans (11.0%), evaluation of extent of disease in 33 scans (16.5%), followup of previous scan in 57 scans (28.5%), other indications in two scans (1.0%), and unclear indications in three scans (1.5%). The PET scan was positive in 124 studies (62.0%); positivity was identified in the thyroid bed on 25 scans, cervical or mediastinal lymph nodes on 105 scans, lung on 28 scans, bone on four scans, and other areas on 14 scans. Therapy following PET scan was surgery in 66 cases (33.0%), chemotherapy or radiation in 23 cases (11.5%), observation in 110 cases (55.0%), and palliative care in one case (0.5%). Disease was identifiable on other imaging in 66% of cases. PET scan results changed management in 59 cases (29.5%). Conclusions: In this academic medical center, the PET scan was utilized in 19% of patients. Indications for the PET scan included conventional indications, such as elevated thyroglobulin with noniodine avid disease, and more controversial uses, such as evaluation of extent of disease or abnormalities on other imaging tests. PET scan results changed management in about 30% of cases.

show abstract

Section: Discussionsupporting

confidence: 77%

“…As such, there remains significant controversy and uncertainty with regards to the optimal way to integrate it into practice (7)(8)(9)(10). Previous studies have shown the ability of the PET scan to localize disease already thought to be present because of detectable thyroglobulin levels (11,12).…”

Section: Introductionmentioning

confidence: 99%

Evaluating Positron Emission Tomography Use in Differentiated Thyroid Cancer

Wiebel

Esfandiari

Papaleontiou

et al. 2015

Thyroid

View full text Add to dashboard Cite

show abstract

“…The early detection of iodinenegative DTC lesions is important, because it triggers an adjustment in the treatment strategy: surgical resection, external-beam radiation therapy (EBRT), or multikinase inhibitor therapy will be selected rather than 131 I treatment. 18 F-FDG PET/CT is useful for the detection of recurrent DTC lesions, especially in patients with iodine-negative tumors and elevated serum thyroglobulin levels (6)(7)(8)(9)(10). Furthermore, recent studies showed that 18 F-FDG PET can detect DTC lesions more accurately under thyroid-stimulating hormone (TSH) stimulation than under TSH suppression (11)(12)(13).…”

mentioning

confidence: 99%

Clinical Utility of ¹⁸F-FDG PET/CT Concurrent with ¹³¹I Therapy in Intermediate–to–High-Risk Patients with Differentiated Thyroid Cancer: Dual-Center Experience with 286 Patients

Lee

et al. 2013

J Nucl Med

View full text Add to dashboard Cite

Patients with differentiated thyroid carcinoma (DTC) are treated with 131 I therapy after total thyroidectomy or surgical resection of recurrent tumor. However, some recurrent DTC lesions are not iodineavid, which affects further treatment planning. The aim of this study was to evaluate the clinical benefit of 18 F-FDG PET/CT performed concurrently with 131 I therapy in DTC patients with intermediate to high risk. Methods: We retrospectively enrolled 286 DTC patients at 2 Korean medical centers who comprised 2 different patient groups: 28 patients who underwent adjuvant 131 I treatment after curative surgical resection of recurrent tumor and 258 patients with intermediate to high risk who underwent 131 I ablation after total thyroidectomy. 131 I therapy and 18 F-FDG PET/CT scanning were performed on the same day. Administration of L-thyroxine was withheld from all enrollees for 4 wk before 131 I treatment. Results: In 39 patients (14%), 18 F-FDG PET/CT detected additional recurrent or metastatic lesions that were not detected on the posttherapy 131 I scan, and the treatment plan was changed for 30 patients (10%) based on such findings. Among the 28 patients receiving 131 I treatment after resection of recurrent tumor, PET/CT detected additional lesions in 46%, and treatment was changed in 43%. Assessing a subgroup of stage T3-T4N1 patients with tumor size . 2.0 cm, among 258 patients undergoing 131 I ablation after total thyroidectomy, we found that 25% had additional positive PET/CT results, and treatment changed for 17%. In contrast, 8% of stage T3-T4N1 patients with tumor size # 2.0 cm, 6% of stage T1-T2N1 patients, and 3% of stage T3-T4N0 patients had additional positive PET/CT findings. Conclusion: 18 F-FDG PET/CT performed concurrently with 131 I therapy detected additional lesions in 14% of DTC patients and was particularly helpful for detecting additional lesions in patients undergoing 131 I therapy after resection of recurrent tumor or in stage T3-T4N1 patients with tumor size . 2.0 cm.

show abstract

“…J. Rosenbaum-Krumme и соавт., в дополнение к 1-й тСВТ, выполнили ПЭТ / КТ 90 пациентам с ДРЩЖ и с распространенными стадиями опухоли. По данным авторов, ПЭТ / КТ улучшила начальное стадирование у 9 % пациентов и поменяла тактику ведения пациента в 21 % случаев (главным образом с T3bN1 стадией и от-даленными метастазами): в отношении 12 % пациентов изменилась лечебная тактика, 9 % были назначены до-полнительные методы обследования, результаты кото-рых оказались в дальнейшем очень полезными для уста-новки окончательного первичного диагноза [41].…”

Section: клинические показанияunclassified

The use of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in patients with differentiated thyroid cancer after initial treatment

Гелиашвили¹,

Важенин²,

Афанасьева³

2017

Opuholi golovy šei

View full text Add to dashboard Cite

18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy

Cited by 72 publications

References 26 publications

Evaluating Positron Emission Tomography Use in Differentiated Thyroid Cancer

Evaluating Positron Emission Tomography Use in Differentiated Thyroid Cancer

Clinical Utility of ¹⁸F-FDG PET/CT Concurrent with ¹³¹I Therapy in Intermediate–to–High-Risk Patients with Differentiated Thyroid Cancer: Dual-Center Experience with 286 Patients

The use of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in patients with differentiated thyroid cancer after initial treatment

Contact Info

Product

Resources

About

18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy

Cited by 72 publications

References 26 publications

Evaluating Positron Emission Tomography Use in Differentiated Thyroid Cancer

Evaluating Positron Emission Tomography Use in Differentiated Thyroid Cancer

Clinical Utility of 18F-FDG PET/CT Concurrent with 131I Therapy in Intermediate–to–High-Risk Patients with Differentiated Thyroid Cancer: Dual-Center Experience with 286 Patients

The use of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in patients with differentiated thyroid cancer after initial treatment

Contact Info

Product

Resources

About

Clinical Utility of ¹⁸F-FDG PET/CT Concurrent with ¹³¹I Therapy in Intermediate–to–High-Risk Patients with Differentiated Thyroid Cancer: Dual-Center Experience with 286 Patients